Efficacy of Venetoclax Combined with Decitabine-Based Treatment for Heavily Pre-Treated Relapsed or Refractory AML Patients in a Real-World Setting

Figures & data

Table 1 The Characteristics of All the Patients and the Comparison of the CR/CRi and the NR Patients

Characteristics	N=22	CR/CRi(N=10)	NR(N=12)	P value
Age(years)	47.5 (12–84)	48(12–81)	47(24–84)	1
Male, n (%)	11(50%)	4(40.0%)	7(58.3%)	0.67
Numbers of chemotherapy in the past	4 (2–10)	3(2–10)	7(3–7)	0.05
AML type				0.09
Primary AML	18(81.8%)	10(100%)	8(66.7%)
Secondary AML	4(18.2%)	0(0%)	4(33.3%)
Relapse or refractory AML				0.44
Relapse AML	8(66.7%)	5(50.0%)	3(25.0%)
Refractory AML	14(63.6)	5(50.0%)	9(75.0%)
Blast cells in the BM before treatment (%)	56 (28–98)	60 (29–98)	56 (28–98)	0.49
Prior HMAs, n (%)	17(77.3%)	6(60.0%)	11(91.7%)	0.21
WBC count at onset	13.8(1.38–171)	40.63(2.3–170)	4.27(1.38–171)	0.10
ELN risk, n (%)				0.64
Favorable	5(22.7%)	3(30.0%)	2(16.7%)
Intermediate	7(31.8%)	2(20.0%)	5(41.7%)
Adverse	10(45.5%)	5(50.0%)	5(41.7%)
FLT3 mutant, n (%)	7(31.8%)	5(50.0%)	2(16.7%)	0.17
NPM1 mutant, n (%)	7(31.8%)	5(50.0%)	2(16.7%)	0.17

Table 2 Gene Mutations of All the Patients (Purple Boxes Represent That the Corresponding Gene Mutation is Positive)

Pts	Remission	FLT3-ITD	FLT3-TKD	Tp53	MLL-AF6	IDH-1/2	NPM1	DNMT3A	KRAS	ASXL1	TET-2	SRSF2	CEBPA	CBFβ-MYH11	AML-ETO
1	NR
2	NR
3	NR
4	NR
5	NR
6	CR
7	NR
8	NR
9	NR
10	CR
11	NR
12	NR
13	CR
14	NR
15	CRi
16	CR
17	NR
18	CR
19	CR
20	CR
21	CR
22	CR

Figure 1 The one-year overall survival (OS) rate of 22 patients was 31.8%, and the median survival time was 6 months (95% CI, 1–9 months).

Figure 2 The one-year overall survival rate of 10 CR/CRi patients was 59.1%, and the 12 NR patients was 10.4%, and there were statistical differences between the two groups (P=0.001).

Figure 3 Remission and survival of the 22 patients.

Table 3 Predictive Gene Mutation in the Literatures

	Favourable	No Impact	Adverse
RUNX1	DiNardo CD,^Citation3 Yu-Wen Wang^Citation17	Erika Morsia^Citation19
IDH1/2.	DiNardo CD,^Citation3 DiNardo CD,^Citation16 Yinjun Lou^Citation18	Erika Morsia^Citation19
FLT3-ITD	DiNardo CD.^Citation16	Aldoss I,^Citation15 Yinjun Lou,^Citation18 Erika Morsia^Citation19	Goldberg AD,^Citation12 Yu-Wen Wang,^Citation17
TP53		Aldoss I,^Citation15 Yinjun Lou,^Citation18 Erika Morsia^Citation19	DiNardo CD,^Citation16 Yu-Wen Wang^Citation17
NPM1	DiNardo CD,^Citation16 Yu-Wen Wang^Citation17	Yinjun Lou^Citation18
RAS			Goldberg AD,^Citation12 Yu-Wen Wang^Citation17
ASXL1	Aldoss I,^Citation15 Yu-Wen Wang^Citation17
TET2	Aldoss I^Citation15
U2AF1			Aldoss I.^Citation15
SRSF2	Yu-Wen Wang^Citation17
SETBP1			Yu-Wen Wang^Citation17
DNMT3A	Erika Morsia^Citation19		Yu-Wen Wang^Citation17
JAK2	Erika Morsia^Citation19
BCOR	Erika Morsia^Citation19

DiNardo CD, Rausch CR, Benton C, et al. Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies. Am J Hematol. 2018;93(3):401–407. doi:10.1002/ajh.2500029218851

 PubMed Web of Science ®Google Scholar

Wang Y-W, Tsai C-H, Lin C-C, et al. Cytogenetics and mutations could predict outcome in relapsed and refractory acute myeloid leukemia patients receiving BCL-2 inhibitor venetoclax. Ann Hematol. 2020;99(3):501–511. doi:10.1007/s00277-020-03911-z31965269

 PubMed Web of Science ®Google Scholar

Morsia E, McCullough K, Joshi M, et al. Venetoclax and hypomethylating agents in acute myeloid leukemia: mayo Clinic series on 86 patients. Am J Hematol. 2020;95(12):1511–1521. doi:10.1002/ajh.2597832833294

 PubMed Web of Science ®Google Scholar

DiNardo CD, Maiti A, Rausch CR, et al. 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, Phase 2 trial. Lancet Haematol. 2020;7(10):e724–e736. doi:10.1016/S2352-3026(20)30210-632896301

 PubMed Web of Science ®Google Scholar

Lou Y, Shao L, Mao L, et al. Efficacy and predictive factors of venetoclax combined with azacitidine as salvage therapy in advanced acute myeloid leukemia patients: a multicenter retrospective study. Leuk Res. 2020;91:106317. doi:10.1016/j.leukres.2020.10631732092584

 PubMed Web of Science ®Google Scholar

Aldoss I, Yang D, Pillai R, et al. Association of leukemia genetics with response to venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia. Am J Hematol. 2019;94(10):E253–E255. doi:10.1002/ajh.2556731259427

 PubMed Web of Science ®Google Scholar

Goldberg AD, Horvat TZ, Hsu M, et al. Venetoclax combined with either a hypomethylating agent or low-dose cytarabine shows activity in relapsed and refractory myeloid malignancies. Blood. 2017;130(Supplement 1):1353.

 Google Scholar